For research use only. Not for therapeutic Use.
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].
Levonadifloxacin (32 μg/mL; 24 h) achieves a 90-99% intracellular reduction of MSSA and MRSA strains phagocytized in THP-1 monocytes with MICs of 0.03 μg/mL and 15.0 ng/mL[1].
Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model[2].
| Catalog Number | M098888 |
| CAS Number | 154357-42-3 |
| Synonyms | (12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid |
| Molecular Formula | C19H21FN2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1 |
| InChIKey | JYJTVFIEFKZWCJ-JTQLQIEISA-N |
| SMILES | CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O |
| Reference | [1]. Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68(12):1716-1722. [2]. Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19. |
